Bioatla to participate in upcoming investor conferences in august

San diego, aug. 03, 2023 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that the company's management will participate in two upcoming investor conferences, to be held in august 2023.
BCAB Ratings Summary
BCAB Quant Ranking